MDedge Hematology and Oncology

2 weeks ago | mdedge.com | Sharon Worcester

Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than 50 years, while overall cancer incidence and mortality rates did not increase, a new study found. Among the more than two million cases of early-onset cancer diagnosed during this period, 63.2% were in women, researchers reported recently in Cancer Discovery.

2 weeks ago | mdedge.com | Liz Scherer

There’s been renewed interest in recent years for concentrated essential oils to replace or complement pharmaceutical treatments. This is especially concerning among patients with chronic obstructive pulmonary disease (COPD), who might be eager to turn to alternatives but are unaware that COPD increases sensitivity to lung irritants like essential oils.

2 weeks ago | mdedge.com | Nancy A. Melville

FROM DDW 2025SAN DIEGO — In the ever-expanding options for colorectal cancer (CRC) screening, blood tests using precision medicine are becoming more advanced and convenient than ever; however, caveats abound, and when it comes to potentially life-saving screening measures, picking the optimal screening tool is critical. Regarding tests, “perfect is not possible,” said William M.

3 weeks ago | mdedge.com | Georgia Williams |Mika M. Tabata |Brett H. Keeling |Margaret Brown

THE DIAGNOSIS: Apocrine HidrocystomaHistology for all 3 lesions demonstrated similar cystic structures lined by a dual layer of epithelial cells, with the outermost layer composed of flattened myoepithelial cells and the inner layer composed of cells with apocrine features (Figure 1). Based on these findings, a diagnosis of apocrine hidrocystoma was made. The patient underwent successful surgical excision shortly thereafter without recurrence at follow-up 1 year later.

3 weeks ago | mdedge.com | Joyce Frieden

Fla. Ruling Affects Levothyroxine RxA ruling by a Florida administrative law judge means pharmacists in that state now are free to substitute generic levothyroxine sodium for brand-name formulations of the drug. The January decision that removed Synthroid, Levoxyl, Levothroid, and Unithroid from the negative formulary list came in response to a petition last August by Mylan Inc., which markets a generic form of levothyroxine.